Anderson Elizabeth M reported option exercise involving 5,070 shares of Revolution Medicines, Inc. at $1.12 for $5.68k on Sep 22, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Director
DIR
Filed Sep 24, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$5,678.40Shares × reported price
Shares traded
5,070Common Stock
Price per share
$1.12Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
14,476Direct
Trade date
Sep 22, 2026Option exercise
Filed
Sep 24, 2026, 6:00 PM ET2-day reporting delay
Accession
0001758247-26-000004Code M · Transaction 229287
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Sep 22, 2026Sell910$191.85−$174,585.41Trade 229288
Sep 22, 2026Sell4,985$192.54−$959,805.42Trade 229289
Sep 22, 2026Sell2,648$193.44−$512,227Trade 229290
Sep 22, 2026Sell1,500$194.59−$291,883.05Trade 229291
Sep 22, 2026Sell100$195.15−$19,515Trade 229292
Sep 22, 2026Option exercise5,070$0.00$0Trade 229293
7 transaction rows in this filing. Joint filers share the same rows.

RVMD price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
RVMD · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +4.8%1w ago +2.5%1d ago −3.6%
Returns since7d +3%30d −6.4%90d180d1y

Footnotes in full

F1: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 23, 2026. F2: The transaction was executed in multiple trades at prices ranging from $191.65 to $191.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3: The transaction was executed in multiple trades at prices ranging from $192.01 to $192.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F4: The transaction was executed in multiple trades at prices ranging from $193.00 to $193.81, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F5: The transaction was executed in multiple trades at prices ranging from $194.04 to $194.96, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F6: Includes 1,191 restricted stock units. F7: Held by David W. Anderson 1996 Irrevocable Trust. F8: Held by Irrevocable Deed of Trust of David W. Anderson and Elizabeth M. Anderson. F9: Fully vested.